Vericel (VCEL) Earning Somewhat Favorable Media Coverage, Analysis Shows
News articles about Vericel (NASDAQ:VCEL) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Vericel earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.1262569517366 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment’s analysis:
- Vericel Corp (NASDAQ:VCEL) Bullish Trend – Live Trading News (livetradingnews.com)
- Identify buying and selling opportunity on Vericel Corporation (VCEL) with Technical Facts – Wall Street Morning (wallstreetmorning.com)
- BRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial (reuters.com)
- Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit (globenewswire.com)
- How Vericel Corporation’s (VCEL) EPS Growth Stacks Up Against Industry Performance (finance.yahoo.com)
Shares of Vericel (NASDAQ:VCEL) opened at $4.73 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50. Vericel has a 52-week low of $2.25 and a 52-week high of $6.30.
A number of brokerages recently weighed in on VCEL. BTIG Research set a $6.00 price target on shares of Vericel and gave the company a “buy” rating in a research report on Monday, October 2nd. ValuEngine downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/10/vericel-vcel-earning-somewhat-favorable-media-coverage-analysis-shows.html.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.